The primary objective was assessment of the clinical and laboratory safety of F ( ab ' ) , which was monitored for 22 days in the group that received one dose ( assessments on days 0-2 , 4 , 8 , 15 , and 22 ) and 33 days in the group that received five doses ( days 0-6 , 8 , 10 , 12 , 19 , 26 , and 33 ) .